187 related articles for article (PubMed ID: 22943060)
1. The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes.
Crook KI; Early PJ; Messenger KM; Muñana KR; Gallagher R; Papich MG
J Vet Pharmacol Ther; 2013 Aug; 36(4):408-11. PubMed ID: 22943060
[TBL] [Abstract][Full Text] [Related]
2. Plasma and serum concentrations of cytarabine administered via continuous intravenous infusion to dogs with meningoencephalomyelitis of unknown etiology.
Early PJ; Crook KI; Williams LM; Davis EG; Muñana KR; Papich MG; Messenger KM
J Vet Pharmacol Ther; 2017 Aug; 40(4):411-414. PubMed ID: 27641693
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs.
Vazquez Fuster IB; Taylor AR; Smith AN; Duran SH; Ravis WR; Jasper SL; Arnold RD
J Vet Intern Med; 2020 Jul; 34(4):1563-1569. PubMed ID: 32442344
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology.
Pastina B; Early PJ; Bergman RL; Nettifee J; Maller A; Bray KY; Waldron RJ; Castel AM; Munana KR; Papich MG; Messenger KM
J Vet Pharmacol Ther; 2018 Oct; 41(5):638-643. PubMed ID: 29761906
[TBL] [Abstract][Full Text] [Related]
5. Analytical determination and pharmacokinetics of robenacoxib in the dog.
Jung M; Lees P; Seewald W; King JN
J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
[TBL] [Abstract][Full Text] [Related]
6. Novel subcutaneous cytarabine infusion with the Omnipod system in dogs with meningoencephalomyelitis of unknown etiology.
Mancini SL; Early PJ; Slater BM; Olby NJ; Mariani CL; Munana KR; Woelfel CW; Schacher JA; Zhong L; Messenger KM
Am J Vet Res; 2022 Jul; 83(9):. PubMed ID: 35895763
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of fentanyl after single intravenous injection and constant rate infusion in dogs.
Sano T; Nishimura R; Kanazawa H; Igarashi E; Nagata Y; Mochizuki M; Sasaki N
Vet Anaesth Analg; 2006 Jul; 33(4):266-73. PubMed ID: 16764592
[TBL] [Abstract][Full Text] [Related]
8. Effect of a constant rate infusion of cytosine arabinoside on mortality in dogs with meningoencephalitis of unknown origin.
Lowrie M; Thomson S; Smith P; Garosi L
Vet J; 2016 Jul; 213():1-5. PubMed ID: 27240905
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes.
Marcucci G; Silverman L; Eller M; Lintz L; Beach CL
J Clin Pharmacol; 2005 May; 45(5):597-602. PubMed ID: 15831784
[TBL] [Abstract][Full Text] [Related]
10. Effects of route of administration and feeding schedule on pharmacokinetics of robenacoxib in cats.
King JN; Jung M; Maurer MP; Schmid VB; Seewald W; Lees P
Am J Vet Res; 2013 Mar; 74(3):465-72. PubMed ID: 23438125
[TBL] [Abstract][Full Text] [Related]
11. Plasma and interstitial fluid pharmacokinetics of enrofloxacin, its metabolite ciprofloxacin, and marbofloxacin after oral administration and a constant rate intravenous infusion in dogs.
Bidgood TL; Papich MG
J Vet Pharmacol Ther; 2005 Aug; 28(4):329-41. PubMed ID: 16050812
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a cytosine arabinoside subcutaneous protocol in dogs with meningoencephalomyelitis of unknown aetiology.
Levitin HA; Foss KD; Li Z; Reinhart JM; Hague DW; Fan TM
J Vet Pharmacol Ther; 2021 Sep; 44(5):696-704. PubMed ID: 34080695
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses.
Lankveld DP; Driessen B; Soma LR; Moate PJ; Rudy J; Uboh CE; van Dijk P; Hellebrekers LJ
J Vet Pharmacol Ther; 2006 Dec; 29(6):477-88. PubMed ID: 17083451
[TBL] [Abstract][Full Text] [Related]
14. Cytosine arabinoside constant rate infusion without subsequent subcutaneous injections for the treatment of dogs with meningoencephalomyelitis of unknown origin.
Stee K; Broeckx BJG; Targett M; Gomes SA; Lowrie M
Vet Rec; 2020 Nov; 187(11):e98. PubMed ID: 32862133
[TBL] [Abstract][Full Text] [Related]
15. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.
Wade M; Baker FJ; Roscigno R; DellaMaestra W; Hunt TL; Lai AA
J Clin Pharmacol; 2004 Jan; 44(1):83-8. PubMed ID: 14681345
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of danofloxacin after single dose intravenous, intramuscular and subcutaneous administration to loggerhead turtles Caretta caretta.
Marín P; Bayón A; Fernández-Varón E; Escudero E; Clavel C; Almela R; Cárceles CM
Dis Aquat Organ; 2008 Dec; 82(3):231-6. PubMed ID: 19244975
[TBL] [Abstract][Full Text] [Related]
17. Plasma pharmacokinetics and tissue fluid concentrations of meropenem after intravenous and subcutaneous administration in dogs.
Bidgood T; Papich MG
Am J Vet Res; 2002 Dec; 63(12):1622-8. PubMed ID: 12492274
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs.
Kumar V; Madabushi R; Lucchesi MB; Derendorf H
J Vet Pharmacol Ther; 2011 Apr; 34(2):130-5. PubMed ID: 21395603
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of florfenicol and its metabolite, florfenicol amine, in dogs.
Park BK; Lim JH; Kim MS; Hwang YH; Yun HI
Res Vet Sci; 2008 Feb; 84(1):85-9. PubMed ID: 17570454
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of cefovecin in dogs.
Stegemann MR; Sherington J; Blanchflower S
J Vet Pharmacol Ther; 2006 Dec; 29(6):501-11. PubMed ID: 17083454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
